Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy

References

• O’Dowd BF, Heiber M, Chan A, et al. A human gene. that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136(1-2):355-60
   PubMed Web of Science ®Google Scholar
• Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004;118(3):119-25
   Google Scholar
• Edinger AL, Hoffman TL, Sharron M, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998;72(10):7934-40
   Google Scholar
• Matsumoto M, Hidaka K, Akiho H, et al. Low stringency hybridization study of the dopamine D4 receptor revealed D4-like mRNA distribution of the orphan seven-transmembrane receptor, APJ, in human brain. Neurosci Lett 1996;219(2):119-22
   Google Scholar
• Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003;84(5):1162-72
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471-6
   PubMed Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74(1):34-41
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54(3):598-604
   PubMed Web of Science ®Google Scholar
• Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132(6):1255-60
   PubMed Web of Science ®Google Scholar
• Salcedo A, Garijo J, Monge L, et al. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept 2007;144(1-3):50-5
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91(5):434-40
   PubMed Web of Science ®Google Scholar
• Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007;357(4):889-95
   Google Scholar
• Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005;65(1):73-82
   PubMed Web of Science ®Google Scholar
• D’Aniello C, Lonardo E, Iaconis S, et al. G protein-coupled receptor APJ and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway. Circ Res 2009;105(3)):231-8
   Google Scholar
• Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 2009;297(5):H1904-13
   PubMed Web of Science ®Google Scholar
• Kang Y, Kim J, Anderson JP, et al. Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 2013;113(1):22-31
   Google Scholar
• Scimia MC, Hurtado C, Ray S, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012;488(7411):394-8
   PubMed Web of Science ®Google Scholar
• Reaux A, De Mota N, Skultetyova I, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001;77(4):1085-96
   PubMed Web of Science ®Google Scholar
• Hus-Citharel A, Bouby N, Frugiere A, et al. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int 2008;74(4):486-94
   PubMed Web of Science ®Google Scholar
• Azizi M, Iturrioz X, Blanchard A, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol 2008;19(5):1015-24
   PubMed Web of Science ®Google Scholar
• Roberts EM, Newson MJ, Pope GR, et al. Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 2009;202(3):453-62
   Google Scholar
• Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538(2-3):162-71
   PubMed Web of Science ®Google Scholar
• Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291(5):1208-12
   PubMed Web of Science ®Google Scholar
• Roberts EM, Pope GR, Newson MJ, et al. Stimulus-specific neuroendocrine responses to osmotic challenges in apelin receptor knockout mice. J Neuroendocrinol 2010;22(4):301-8
   Google Scholar
• Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146(4):1764-71
   PubMed Web of Science ®Google Scholar
• Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008;8(5):437-45
   PubMed Web of Science ®Google Scholar
• Dray C, Debard C, Jager J, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 2010;298(6):E1161-9
   PubMed Web of Science ®Google Scholar
• Castan-Laurell I, Boucher J, Dray C, et al. Apelin, a novel adipokine over-produced in obesity: friend or foe? Mol Cell Endocrinol 2005;245(1-2):7-9
   PubMed Web of Science ®Google Scholar
• Higuchi K, Masaki T, Gotoh K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007;148(6):2690-7
   PubMedGoogle Scholar
• Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006;114(10):544-8
   PubMed Web of Science ®Google Scholar
• Cavallo MG, Sentinelli F, Barchetta I, et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. PLoS One 2012;7(12):e51236
   PubMed Web of Science ®Google Scholar
• Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 2009;19(11):1574-80
   PubMed Web of Science ®Google Scholar
• Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, et al. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol Endocrinol Metab 2007;292(1):E7-15
   Google Scholar
• Newson MJ, Roberts EM, Pope GR, et al. The effects of apelin on hypothalamic-pituitary-adrenal axis neuroendocrine function are mediated through corticotrophin-releasing factor- and vasopressin-dependent mechanisms. J Endocrinol 2009;202(1):123-9
   PubMed Web of Science ®Google Scholar
• El Messari S, Iturrioz X, Fassot C, et al. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem 2004;90(6):1290-301
   PubMed Web of Science ®Google Scholar
• Proceedings of the British Pharmacological Society. Available from: www.pA2online.org/abstracts/Vol10Issue1abst003P.pdf
   Google Scholar
• Lin Q, Lu J, Yanagisawa H, et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998;125(22):4565-74
   Google Scholar
• Naya FJ, Black BL, Wu H, et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 2002;8(11):1303-9
   Google Scholar
• Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997;276(5317):1404-7
   Google Scholar
• Offermanns S, Mancino V, Revel JP, Simon MI. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997;275(5299):533-6
   Google Scholar
• Ruppel KM, Willison D, Kataoka H, et al. Essential role for Galpha13 in endothelial cells during embryonic development. Proc Natl Acad Sci USA 2005;102(23):8281-6
   Google Scholar
• Skeggs LT, Dorer FE, Kahn JR, et al. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 1976;60(6):737-48
   Google Scholar
• Skeggs LT, Dorer FE, Levine M, et al. The biochemistry of the renin-angiotensin system. Adv Exp Med Biol 1980;130:1-27
   PubMedGoogle Scholar
• Oppermann M, Diverse-Pierluissi M, Drazner MH, et al. Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. Proc Natl Acad Sci USA 1996;93(15):7649-54
   Google Scholar
• Olivares-Reyes JA, Smith RD, Hunyady L, et al. Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor. J Biol Chem 2001;276(41):37761-8
   Google Scholar
• Kim J, Ahn S, Ren XR, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci USA 2005;102(5):1442-7
   Google Scholar
• Zhang J, Ferguson SS, Barak LS, et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem 1996;271(31):18302-5
   Google Scholar
• Oakley RH, Laporte SA, Holt JA, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000;275(22):17201-10
   Google Scholar
• McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000;290(5496):1574-7
   PubMed Web of Science ®Google Scholar
• Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 2001;98(5):2449-54
   PubMed Web of Science ®Google Scholar
• DeFea KA, Zalevsky J, Thoma MS, et al. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000;148(6):1267-81
   PubMed Web of Science ®Google Scholar
• Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001;33(1):3-7
   Google Scholar
• Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003;100(19):10782-7
   Google Scholar
• Gaborik Z, Jagadeesh G, Zhang M, et al. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 2003;144(6):2220-8
   Google Scholar
• Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005;115(11):3045-56
   Google Scholar
• Rakesh K, Yoo B, Kim IM, et al. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 2010;3(125):ra46
   Google Scholar
• Holloway AC, Qian H, Pipolo L, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002;61(4):768-77
   Google Scholar
• Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 2007;100(5):296-301
   Google Scholar
• Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci USA 2010;107(2):628-32
   PubMed Web of Science ®Google Scholar
• Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007;28(8):416-22
   PubMed Web of Science ®Google Scholar
• Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010;335(3):572-9
   Google Scholar
• Cody RJ, Binkley PF, Haas GJ, Brown DM. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat. Am J Hypertens 1995;8(5 Pt 1):500-8
   Google Scholar
• Boerrigter G, Lark MW, Whalen EJ, et al. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011;4(6):770-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/results?term=TRV120027&Search=Search
   Google Scholar
• Yi XP, Gerdes AM, Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension 2002;39(6):1058-63
   PubMedGoogle Scholar
• Zhang Y, Matkovich SJ, Duan X, et al. Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure. Circ Heart Fail 2011;4(5):659-68
   Google Scholar
• Yi XP, Zhou J, Baker J, et al. Myocardial expression and redistribution of GRKs in hypertensive hypertrophy and failure. Anat Rec A Discov Mol Cell Evol Biol 2005;282(1):13-23
   PubMedGoogle Scholar
• Martini JS, Raake P, Vinge LE, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 2008;105(34):12457-62
   Google Scholar
• Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998;280(5363):574-7
   Google Scholar
• Dzimiri N, Muiya P, Andres E, Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol 2004;489(3):167-77
   Google Scholar
• Gold JI, Gao E, Shang X, et al. Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ Res 2012;111(8):1048-53
   Google Scholar
• Gold JI, Martini JS, Hullmann J, et al. Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS One 2013;8(3):e57324
   Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7-13
   PubMed Web of Science ®Google Scholar
• Metra M, Cas LD, di Lenarda A, Poole-Wilson P. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 2004;9(2):123-30
   Google Scholar
• Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102(5):546-51
   PubMed Web of Science ®Google Scholar
• Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 2006;98(8):1115-19
   PubMedGoogle Scholar
• Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007;117(9):2445-58
   Google Scholar
• Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006;4(3):417-32
   Google Scholar
• Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J 2008;72(11):1725-9
   Google Scholar
• Mangmool S, Shukla AK, Rockman HA. Beta-arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol 2010;189(3):573-87
   Google Scholar